[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SUK MIN SEO\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100632368","ivus-guided-vs-angiography-guided-pci-in-acute-coronary-syndrome-100632368",false,"NCT07512778","IVUS-Guided vs Angiography-Guided PCI in Acute Coronary Syndrome","Clinical Impact of Intravascular Ultrasound-guided vs. Angiography-guided Coronary Stenting in Patients With Acute Coronary Syndrome: Multicenter, Randomized Control Trial (SAINT-IVUS)","SAINT-IVUS","Inclusion Criteria:\n\n1. Patients 19 years of age or older\n2. Patients with unstable angina pectoris, and acute MI including NSTEMI or STEMI.\n3. Coronary artery disease defined as \\>70% stenosis (reference vessel diameter 2.5 - 5.0 mm based on operator assessment) with identifiable culprit lesion indicated stent implantation\n4. All lesions must be suitable for treatment with the Synergy stent system, or other Synergy platform iteration\n5. The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Age \\>90 years\n2. Subject has known hypersensitivity or contraindication to device material and its degradants (everolimus, poly(L-lactide), poly(DL-lactide), lactide, lactic acid) and cobalt, chromium, nickel, platinum, tungsten, acrylic, and fluoro polymers that cannot be adequately premedicated.\n3. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to antiplatelet drugs, including both aspirin and P2Y12 inhibitors\n4. An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs within 6 m after the procedure.\n5. Cardiogenic shock\n6. Restenotic lesions\n7. Compromised left ventricular dysfunction (LVEF \\\u003C30%)\n8. At the time of screening, the subject has a malignancy that is not in remission\n9. Non-cardiac co-morbidities with a life expectancy less than 1 year\n10. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.\n11. Subject belongs to a vulnerable population (per investigator's judgment) or subject unable to read or write\n12. Concern for inability of the patient to comply with study procedures and\u002For follow-up (e.g., alcohol or drug abuse)\n13. Pregnancy","ALL","19 Years","90 Years",{"count":21,"type":22},1500,"ESTIMATED","INTERVENTIONAL",[25],"NA","Coronary artery disease is associated with substantial morbidity and mortality worldwide. Percutaneous coronary intervention (PCI) is a pivotal procedure for the treatment of coronary artery disease. Although coronary angiography (CA) is the standard imaging modality used for coronary stent implantation, it provides only two-dimensional images of the coronary arteries. Intravascular ultrasound (IVUS) can provide additional information on plaque characteristics and vessel morphology, which may facilitate optimal stent sizing and procedural optimization. However, IVUS requires additional time and cost and may increase procedural complexity. Evidence regarding the clinical benefit of IVUS-guided PCI in patients with acute coronary syndrome (ACS) remains limited.\n\nThis study is a prospective, multicenter, randomized controlled trial designed to compare IVUS-guided PCI versus angiography-guided PCI in patients with ACS. A total of 1,500 participants will be randomized 1:1 to either the IVUS-guided group or the angiography-guided group. Participants will be recruited from 15 PCI centers in Korea. The primary outcome is target vessel failure at 2 years.",[28],"Acute Coronary Syndromes (ACS)",[30,31,32],"Intravascular Ultrasound","IVUS-guided PCI","Angiography-guided PCI","RECRUITING","2026-04-02",{"date":36,"type":37},"2026-04-06","ACTUAL",{"date":39,"type":37},"2025-03-13",{"date":41,"type":22},"2031-12-31",{"name":43,"class":44},"SUK MIN SEO","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100629775","fexuprazan-for-prevention-of-upper-gastrointestinal-bleeding-in-high-bleeding-risk-patients-receiving-dual-antiplatelet-therapy-100629775","NCT07479056","Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy","Randomized Active-Controlled Trial Evaluating Fexuprazan for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention-Fexuprazan for Patients With Dual Antiplatelet Therapy Trial","SAINT-FEXUDAPT","Inclusion Criteria:\n\n* All four conditions below must be met.\n\n  1. Patients who are 20 years of age or older, have undergone coronary artery stent implantation for coronary artery disease, and require dual antiplatelet therapy for 6 months or longer.\n  2. Patients are considered to be at high bleeding risk if at least 1 criteria are met (Based on clinical recommendations (6,7,10,14-16) and expert consensus documents (17-19)) 1) Age ≥65 y 2) Low body weight (\\\u003C55 Kg for men, \\\u003C50 Kg for women) 3)Hemoglobin \\\u003C11g\u002FdL 4) Platelet count \\\u003C100×109\u002FL 5) Severe CKD: eGFR \\\u003C30mL\u002Fmin\u002F1.73m2,5 or on hemodialysis 6) Anticipated use of long-term oral anticoagulation (warfarin or direct-acting oral anticoagulants) 7) Long-term use of oral NSAIDs or steroids 8) Heart failure 9) A history of previous gastric or duodenal ulcer. 10) A history of previous gastrointestinal bleeding. 11)Previous or confirmed Helicobacter pylori infection\n  3. A voluntary participant in this clinical trial who has provided written consent, or a legal guardian who has provided written consent on behalf of the participant.\n  4. Those who agree to use a medically valid method of contraception\\* (including conditions in which pregnancy is medically impossible) during the clinical trial period Women who are medically unable to become pregnant can participate in this clinical trial: women who have undergone menopause (amenorrhea for more than 24 months), hysterectomy, salpingectomy, or bilateral oophorectomy, etc.\n* Medically valid contraceptive methods: intrauterine device (Loop, Mirena), physical barrier method (male condom, female condom (femidom)), subcutaneous contraception (Implanon, etc.), long-acting contraceptive injection, or tubectomy and ligation, vasectomy, etc. ( However, oral contraceptives cannot be used during this clinical trial, and it is recommended to use double contraception to prevent pregnancy while participating in this trial.)\n\nExclusion Criteria:\n\n1. Patients who have a hypersensitivity reaction to the components of this clinical trial drug or benzimidazole-based drugs or have a history of clinically significant hypersensitivity reaction\n2. Patients with contraindications to antiplatelet agents, such as allergies.\n3. Genetic blood coagulation disorders\n4. Cases in which the investigator determines that the use of dual antiplatelet therapy is difficult due to severe liver cirrhosis, thrombocytopenia, or other medical conditions.\n5. Hemodynamically unstable at the time of randomization (cardiogenic shock, uncontrolled arrhythmia, severe heart failure: NYHA Class IV).\n6. Patients with warning symptoms suspected of digestive malignancy (unintentional significant weight loss, recurrent vomiting, dysphagia, hematemesis, melena, etc.) within the past 3 months\n7. Patients with malignancy or serious illnesses with an expected survival of less than 1 year.\n8. Severe anemia (hemoglobin \\\u003C 8 g\u002FdL) or blood transfusion within 4 weeks of randomization.\n9. Active liver disease or impaired liver function (AST or ALT greater than three times the upper limit of normal).\n10. Advanced renal dysfunction: eGFR less than 30 mLmin\u002F1.73m2 or patients receiving dialysis\n11. Patients taking drugs contraindicated for this clinical trial drug (e.g., patients taking atazanavir, nelfinavir, or rilpivirine-containing preparations)\n12. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n13. Concurrently taking CYP 3A4 and p-glycoprotein (P-GP) inhibitors.\n14. Dementia or individuals unable to understand the trial procedures or comply with the trial requirements\n15. Pregnant or breastfeeding women, or women planning to become pregnant\n16. Individuals with active infections, significant hematologic, renal, metabolic, gastrointestinal, endocrine disorders, or any other reason the investigator deems the subject unsuitable for participation in the clinical trial","20 Years",{"count":56,"type":22},400,[25],"This study evaluates whether fexuprazan is effective in preventing upper gastrointestinal bleeding and related upper gastrointestinal clinical events in high bleeding risk patients who require dual antiplatelet therapy after coronary stent implantation.\n\nA total of 400 participants at a single center will be randomly assigned in a 1:1 ratio within 48 hours after stent implantation to receive either fexuprazan 40 milligrams or lansoprazole 30 milligrams once daily for 6 months. The study will compare upper gastrointestinal clinical events during follow-up",[28,60],"Coronary Artery Disease (CAD)",{"date":62,"type":37},"2026-04-08",{"date":64,"type":37},"2024-10-24",{"date":66,"type":22},"2028-12-31",{"name":43,"class":44},""]